Business Wire - September 29, 2009
Advanced Biological Laboratories S.A (ABL) and Evivar Medical Pty Ltd (Evivar) today announced the completion of agreements to cross-licence their respective intellectual property portfolios, and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis B.
TherapyEdge is a comprehensive patient record hospital information system to be used for data and patient management, monitoring and reporting applications. It is already integrating decision support and expert systems for HIV or TB disease management, allowing personalized therapy selection and optimal diagnostic monitoring and evaluation. Through HL7, TherapyEdge has already interfaced with Laboratory and Hospital Information Systems in Europe, Asia, Africa and soon in the USA. It can also be combined with the ViroScore Suite sequence database and drug resistance (HIV and TB) interpretation systems to create a powerful global clinical and research patient management system. It is used in over 75 hospitals and clinical settings in 35 countries as their primary longitudinal patient record and research tool, by government organizations to track program indicators and expenditures, by researchers to learn more about the resistance profiles and by virologists and clinicians to improve the quality of care.
The Evivar SeqHepB system can be used to identify HBV mutations present in the patient and to determine and predict resistance levels to the various available medications. SeqHepB is an unique viral genomics sequence analysis program that is linked to a dynamic and centralized HBV genomic database to enable virologists in their research efforts. Evivar provides a secure, on-line decision support tool for those interpreting HBV drug resistance and treating patients with HBV. Evivar enables physicians to personalize the treatment of patients with chronic HBV, selecting the right drug, at the right time in response to the mutations diagnosed. The SeqHepB system and intellectual property emanates from the laboratory of Professor Stephen Locarnini, a world renowned expert in Hepatitis B and antiviral resistance, from Melbourne Health (Melbourne, Australia).
"Our partnership with Evivar Medical to develop an interface between TherapyEdge and the Evivar SeqHepB systems is an important milestone for ABL's platform to enable physicians in their ability to manage more and more complex treatment and diagnostics decisions," said Dr Chalom Sayada, President and CEO of ABL. "Evivar's expertise and disease management platform for Hepatitis B is a truly complimentary addition to ABL's infectious diseases management technologies"
Mr Bernie Romanin, CEO of Evivar Medical, stated "We are very excited about our strategic partnership with ABL. The combined platforms offer virologists and physicians diagnosing and treating Hepatitis and HIV with enhanced clinical and research management tools. Optimized patient disease management systems like TherapyEdge and SeqHepB, leading to improved personalized care, will enable the development of the necessary solutions to achieve substantial cost savings for our Hospitals".
About ABL, S.A.: Advanced Biological Laboratories (ABL), S.A., is a biotech company founded in 2000 as a spin-off from the European academic research center, CRP-Sante Luxembourg and in 2004, acquired the control of TherapyEdge, Inc. TherapyEdge is a biotech company founded in 2000 as a spin-off from Triangle Pharmaceuticals, Inc., which had been acquired by Gilead Sciences in December 2002. TherapyEdge and ABL's expertise lies within infectious diseases, with particular focus on resistance patterns and clinical patient management for HIV-1, tuberculosis, hepatitis,malaria and human papillomavirus (HPV) infections. http://www.therapyedge.com
About Evivar Medical: Evivar is a joint venture company established in February 2006 to provide accurate and timely therapy management for Hepatitis B patients through its SeqHepB programme - a web-based decision support tool to assist physicians to optimise and individualise the treatment schedule of patients with chronic hepatitis B. The Company provides therapy management services to chronically infected Hepatitis B patients. Evivar is also the exclusive licensee of intellectual property relating to methods for detecting drug resistance to Hepatitis B and variants of Hepatitis B.http://www.evivar.com
Contacts
Advanced Biological Laboratories (ABL), S. A.
Phone: +352 2638 8921
Fax: +352 2638 8938
Email: chalom@ablsa.com
Attention: Chalom B. Sayada (CEO)
or
Evivar Medical Pty Ltd
Phone: +61 3 9662 4900
Fax: + 61 3 9662 4933
Email: b.romanin@evivar.com
Attention: Bernie Romanin
090929
BW090940
Copyright © 2009 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .